ClinicalTrials.gg
Enrolling by invitationNCT07934355HiPERionUpdated Nov 12, 2026

Evaluation of the Efficacy and Safety of High-Flow Oxygen Therapy Compared With a Nasal Positive Airway Pressure (nPAP) Mask Using Transcutaneous Capnometry During Endoscopic Procedures in High-Risk Patients

An interventional study of High-Flow Nasal Cannula (HFNC) Oxygen Therapy and nPAP in Sedation Complication, Colonoscopy (Procedure) and Gastroscopy, sponsored by University of Ulm. Enrolling by invitation at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of Ulm · Not applicable, Interventional, and Other

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The HiPERion Trial is a prospective, randomized, controlled, non-inferiority study designed to compare the efficacy and safety of two oxygen and respiratory support methods during sedated endoscopic procedures in patients at increased risk of respiratory complications.

Patients with significant pre-existing medical conditions (American Society of Anesthesiologists [ASA] physical status III or IV) have an increased risk of breathing-related complications during endoscopic procedures performed under sedation. These complications include low blood oxygen levels (hypoxemia) and elevated carbon dioxide levels in the blood (hypercapnia).

The study will compare two respiratory support methods: high-flow nasal cannula (HFNC) oxygen therapy and a nasal positive airway pressure (nPAP) system using the SuperNO2VA mask. Both methods are used to support breathing and maintain adequate oxygen levels during medical procedures. However, they differ in their technical approach and in the way they support ventilation.

A total of 140 adult patients undergoing diagnostic or therapeutic endoscopic procedures lasting more than 15 minutes will be enrolled at the University Hospital Ulm, Germany. Eligible participants will be randomly assigned to receive either HFNC oxygen therapy or respiratory support via the nPAP mask during the procedure.

Throughout the endoscopic procedure, patients will receive standard clinical monitoring, including measurement of oxygen saturation, heart rate, and blood pressure. In addition, carbon dioxide levels will be continuously monitored using a non-invasive transcutaneous capnometry sensor attached to the patient's forehead. This method allows continuous measurement of carbon dioxide levels through the skin without the need for additional blood sampling.

The primary objective is to compare the occurrence of hypoxemic events between the two respiratory support methods. Hypoxemia is defined as a decrease in oxygen saturation below 90% lasting more than 10 seconds. Severe hypoxemic events, defined as a decrease in oxygen saturation below 80% lasting more than 10 seconds, will also be assessed.

Secondary objectives include comparing changes in transcutaneous carbon dioxide levels during the procedure, the number of interventions required to maintain an open airway or optimize respiratory support, and the occurrence of adverse events.

The study aims to determine whether respiratory support using the nPAP mask is not inferior to HFNC oxygen therapy in terms of safety and prevention of hypoxemic events during endoscopic procedures in high-risk patients. The findings may help identify an effective and safe respiratory support strategy for this patient population.

02

Conditions studied

  • Sedation Complication
  • Colonoscopy (Procedure)
  • Gastroscopy
  • ERCP Airway Management
  • Airway Management
03

In context

Lead sponsor

University of Ulm is the lead sponsor of 145 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • (ASA) physical status III or IV.
  • Patients undergoing diagnostic or therapeutic endoscopic procedures with an expected duration of more than 15 minutes.
  • Written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients unable or unwilling to provide .
  • Known pregnancy.
  • Intolerance or to sedation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    HFNC Group

    High-Flow Nasal Cannula (HFNC) Oxygen Therapy

    Device: High-Flow Nasal Cannula (HFNC) Oxygen Therapy

  • Active comparator
    nPAP Group

    Nasal Positive Airway Pressure (nPAP) Using the SuperNO2VA Mask

    Device: nPAP

Interventions

  • DeviceHigh-Flow Nasal Cannula (HFNC) Oxygen Therapy

    Patients assigned to the HFNC group will receive high-flow nasal cannula oxygen therapy during the endoscopic procedure. The oxygen flow rate will be set at 40 L/min with an inspired oxygen concentration (FiO₂) of 40%. Transcutaneous carbon dioxide levels will be continuously monitored using a non-invasive forehead sensor. Standard monitoring of peripheral oxygen saturation (SpO₂), heart rate, and blood pressure will be performed throughout the procedure.

  • DevicenPAP

    Patients assigned to the nPAP group will receive respiratory support using a nasal positive airway pressure (nPAP) system with the SuperNO2VA nasal mask throughout the endoscopic procedure. Transcutaneous carbon dioxide levels will be continuously monitored using a non-invasive forehead sensor. Standard monitoring of peripheral oxygen saturation (SpO₂), heart rate, and blood pressure will be performed throughout the procedure.

06

What researchers measure

Primary outcomes

  1. Number of Hypoxemic Events

    Number of hypoxemic events, defined as a peripheral oxygen saturation (SpO₂) below 90% lasting more than 10 seconds, during the endoscopic procedure.

    Time frame: During the endoscopic procedure.

  2. Number of Severe Hypoxemic Events

    Number of severe hypoxemic events, defined as a peripheral oxygen saturation (SpO₂) below 80% lasting more than 10 seconds, during the endoscopic procedur

    Time frame: During the endoscopic procedure.

Secondary outcomes

  1. Change in Transcutaneous Carbon Dioxide Levels (tcPCO₂)

    Difference between the initial transcutaneous carbon dioxide level (tcPCO₂) and the mean tcPCO₂ level measured during the endoscopic procedure. Continuous non-invasive monitoring will be performed using a transcutaneous forehead sensor.

    Time frame: During the endoscopic procedure.

  2. Number of Airway Support Interventions

    Number of airway support interventions required during the endoscopic procedure, including head repositioning and repositioning or adjustment of the nPAP mask or HFNC nasal cannula.

    Time frame: During the endoscopic procedure.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartActual
Oct 13, 2026
Primary completionEst.
Mar 13, 2027
CompletionEst.
Jun 13, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934355
Lead sponsor
University of Ulm
Responsible party
Thomas Seufferlein (Chief of Internal Medicine I, University of Ulm) — Principal investigator
First posted
Nov 12, 2026
Start date
Oct 13, 2026
Primary completion
Mar 13, 2027 (estimated)
Completion
Jun 13, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion